Dr. Silverberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2150 Pennsylvania Ave NW
Ste 2B-430
Washington, DC 20037Phone+1 202-741-2625
Summary
- Dr. Jonathan Silverberg is a dermatologist in Washington, DC and is affiliated with George Washington University School of Medicine and Health Sciences. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 8 years. He is experienced in general dermatology, atopic dermatitis, contact dermatitis, allergic contact dermatitis, and eczema.
Education & Training
- Icahn School of Medicine at Mount SinaiResidency, Dermatology, 2010 - 2013
- SUNY Downstate Health Sciences UniversityInternship, Internal Medicine, 2009 - 2010
- State University of New York Downstate Medical Center College of MedicineClass of 2009
Certifications & Licensure
- OR State Medical License 2012 - Present
- DC State Medical License 2019 - 2024
- MD State Medical License 2019 - 2021
- IL State Medical License 2013 - 2020
- NY State Medical License 2012 - 2014
- American Board of Dermatology Dermatology
Publications & Presentations
PubMed
- Drug survival of alitretinoin treatment for chronic hand eczema: A Danish nationwide cohort study.Amalie Thorsti Møller Rønnstad, Mia-Louise Nielsen, Christoph Schlapbach, Emma Guttman-Yassky, Jonathan I Silverberg
Journal of the European Academy of Dermatology and Venereology. 2025-02-01 - Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.Eric L Simpson, Lawrence F Eichenfield, Kim A Papp, Seth B Forman, Adelaide A Hebert
Dermatitis. 2025-01-10 - Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging...Jonathan I Silverberg, Lawrence F Eichenfield, Andrew Blauvelt, Alan D Irvine, Emma Guttman-Yassky
The British Journal of Dermatology. 2025-01-07
Journal Articles
- Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, Hernan Valdez, JAMA Dermatology
- Dupilumab Provides Important Clinical Benefits to Patients with Atopic Dermatitis Who Do Not Achieve Clear or Almost Clear Skin According to the Investigator's Global ...J I Silverberg, The British Journal of Dermatology
- Inpatient Burden of Juvenile Dermatomyositis Among Children in the United StatesMichael C Kwa, Jonathan I Silverberg, BioMed Central
- Join now to see all
Authored Content
- Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic DermatitisJune 2020
Press Mentions
- Chronic Urticaria: What’s in the Treatment Pipeline?December 11th, 2024
- Enveda Announces First Candidate Discovered from Nature Using AI Advances to Clinical TrialsNovember 13th, 2024
- Defining Treatment Success in Chronic Spontaneous UrticariaNovember 7th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: